The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …"

HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy. حسب Wen Wang (6570)

"…All the data in this study was presented as mean ± SEM.</p>…"

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  حسب Beatrice T. Nganso (4114768)

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. حسب Peiqi Yin (6533747)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i>_<i>k</i>; a–c and d–f decreasing porosity for outward and inward protection... حسب Akshay Anand (118579)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات: